Home > Products > Antibodies > Biosimilars

Anti-Human CD27 Ligand/TNFSF7/CD70 Reference Antibody (Varlilumab, RUO) (HB796016)

Datasheet Share product Copy info

Anti-Human CD27 Ligand/TNFSF7/CD70 Reference Antibody (Varlilumab, RUO)

Anti-Human CD27 Ligand/TNFSF7/CD70 Reference Antibody (Varlilumab, RUO)

Price(USD): $

Spec:

100ug
1mg

Number:

Contact us

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB796016
Description	Varlilumab (HB796016) is a research-grade recombinant antibody targeting CD27L. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	CD27L receptor, TNFRSF7, T14, CD27 antigen, Tumor necrosis factor receptor superfamily member 7, CD27, T-cell activation antigen CD27
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P26842
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	1F5, CDX-1127, 1393344-72-3
Background	CD27 antigen is a ~29 kDa protein. Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells. The CD70-CD27 signaling pathway mediates antigen-specific T-cell activation and expansion which in turn provides immune surveillance of B-cells. Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory. In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis. Negatively regulates the function of Th2 lymphocytes in the adipose tissue. 1. Izawa, K. et al. (2017) The Journal of experimental medicine 214, 73-89. PMID: 28011863 2. Jaeger-Ruckstuhl, CA. et al. (2024) Immunity 57, 287-302.e12. PMID: 38354704
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Varlilumab.

References

Datasheet

Anti-Human CD27 Ligand/TNFSF7/CD70 Reference Antibody (Varlilumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list

Anti-Human CD27 Ligand/TNFSF7/CD70 Reference Antibody (Varlilumab, RUO)